OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Hurvitz on the Results of Subgroup Analyses From DESTINY-Breast03 in HER2+ Breast Cancer

December 9th 2021

Sara A. Hurvitz, MD, discusses the results of subgroup analyses from the phase 3 DESTINY-Breast03 trial in patients with HER2-positive metastatic breast cancer.

Dr. Azzi on the Utility of Signatera as a Preferred ctDNA Assay in CRC

December 8th 2021

Georges Azzi, MD, discusses the utility of the Signatera circulating tumor DNA assay as a preferred test in colorectal cancer (CRC).

Dr. Lipson on the Role of ctDNA Testing in Melanoma

December 8th 2021

Evan J. Lipson, MD, discusses the role of circulating tumor DNA testing in melanoma.

Dr. Spitalnik on Goals for the Hemanext® Blood Storage System in Hematologic Malignancies

December 8th 2021

Steven L. Spitalnik, MD, discusses the goals for the Hemanext® blood storage system in patients with hematologic malignancies.

Dr. Arnaoutakis on the ADAURA Trial Examining Osimertinib in EGFR-Mutant Lung Cancer

December 8th 2021

Konstantinos Arnaoutakis, MD, discusses the phase 3 ADAURA trial examining osimertinib in the adjuvant treatment of patients with EGFR-mutant lung cancer.

Dr. Anders on Leveraging ADCs in Metastatic TNBC

December 8th 2021

Carey K. Anders, MD, discusses leveraging antibody-drug conjugates in the treatment of patients with metastatic triple-negative breast cancer.

Dr. Kalinsky on Updated Results From the RxPONDER Trial in HR+/HER2- Breast Cancer

December 8th 2021

Kevin Kalinsky, MD, MS, discusses updated results from the phase 3 RxPONDER trial in patients with hormone receptor-positive, HER2-negative breast cancer.

Dr. Fernandez on the Results of a Study Examining Low HER2 Expression in Breast Cancer

December 8th 2021

Aileen I. Fernandez, PhD, discusses the results of a study examining low HER2 expression in breast cancer.

Dr. Vaishampayan on the Utility of FGFR Inhibitors in Urothelial Cancer

December 8th 2021

Ulka Nitin Vaishampayan, MBBS, discusses the utility of FGFR inhibitors in metastatic urothelial cancer.

Dr. Shore on the Rationale for the Phase 2 ENACT Trial in Prostate Cancer

December 8th 2021

Neal D. Shore, MD, FACS, discusses the rationale for the open-label, randomized phase 2 ENACT trial in prostate cancer.

Dr. Lonial on the Management of Belantamab Mafodotin–Related Keratopathy in Multiple Myeloma

December 8th 2021

Sagar Lonial, MD, FACP, discusses the management of belantamab mafodotin-blmf–related keratopathy in patients with relapsed/refractory multiple myeloma.

Dr. Raghav on Treatment Considerations in Metastatic CRC

December 8th 2021

Kanwal Raghav, MBBS, MD, discusses treatment considerations in metastatic colorectal cancer.

Dr. Erickson on the Varying Safety Profiles of Select PARP Inhibitors in Ovarian Cancer

December 7th 2021

Britt Erickson, MD, discusses the toxicity profiles of available PARP inhibitors used in the treatment of patients with ovarian cancer.

Dr. Boland on Leveraging Triplet Chemo Regimens in Non-Resectable Liver-Only mCRC

December 7th 2021

Patrick Boland, MD, discusses therapeutic options for patients with patients with liver-only metastatic colorectal cancer.

Dr. Boland on Determining When to Utilize Up-front Perioperative Chemotherapy in CRC

December 6th 2021

Patrick Boland, MD, discusses determining when to utilize up-front perioperative chemotherapy for patients with colorectal cancer with liver metastases.

Dr. Anders on Navigating the Treatment Landscape of Metastatic TNBC

December 6th 2021

Carey K. Anders, MD, discusses navigating the treatment landscape of metastatic triple-negative breast cancer.

Dr. Bestvina on Challenges With Interpreting Molecular Reports in Lung Cancer

December 6th 2021

Christine Bestvina, MD, discusses challenges with interpreting molecular reports in lung cancer.

Dr. Qin on Treatment Considerations for Immunotherapy in NSCLC

December 6th 2021

Angel Qin, MD, discusses treatment considerations for immunotherapy in patients with newly diagnosed non–small cell lung cancer.

Dr. Qin on Selecting Single-Agent Immunotherapy or Chemoimmunotherapy in NSCLC

December 3rd 2021

Angel Qin, MD, discusses selecting between single-agent immunotherapy or combination chemoimmunotherapy in non–small cell lung cancer.

Dr. Iqbal on Determining Whether to Start With Regorafenib or TAS-102 in mCRC

December 3rd 2021

Syma Iqbal, MD, discusses determining whether to start with regorafenib (Stivarga) or trifluridine/tipiracil (TAS-102; Lonsurf) in metastatic colorectal cancer (mCRC).